1. Current landscape of targeted therapy in hormone receptor-positive and HER2-negative breast cancer;Andrahennadi;Curr Oncol,2021
2. The place of chemotherapy in the evolving treatment landscape for patients with HR-positive/HER2-negative MBC;Twelves;Clin Breast Cancer,2022
3. Decision of adjuvant systemic treatment in HR+ HER2- early invasive breast cancer: which biomarkers could help?;Alexandre;Cancer Manag Res,2019
4. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics;Nelson;PLoS One,2022
5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed April 6, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN, National Comprehensive Cancer Network® (NCCN®).